Despite the current approval of HDAC enzyme activity inhibitors such as Vorinostat (SAHA), Belinostat, Panobinostat, and Romidepsin for the treatment of diseases like myeloma and lymphoma, these HDAC inhibitors have demonstrated limited efficacy in solid tumors and are associated with certain side effects. Here, HDAC9 is linked to plasma cell myeloma.